The U21-1283 monoclonal antibody specifically recognizes Neuropilin-1 (NRP1), also known as CD304, Blood dendritic cell antigen 4 (BDCA4), and Vascular endothelial cell growth factor 165 receptor (VEGF165R). CD304 is a type I transmembrane glycoprotein involved in the development of the nervous and cardiovascular systems. It mediates the interaction, growth, survival, and migration of a variety of normal and tumor cells. CD304 is expressed on neurons, thymocytes, regulatory T cells, a subset of T follicular helper cells, dendritic cells, endothelial cells, and certain tumor cells. Neuropilin-1 has a very short cytoplasmic domain and interacts with various coreceptors to form ligand-binding, signal-transducing receptor complexes. CD304 complexes with Plexin-A family members to bind chemorepellent Class 3 Semaphorins and guide neuronal axon growth. It also functions as a coreceptor with VEGFR2/CD309 to stimulate angiogenesis in response to VEGF165. CD304 mediates the interactions between some T cells and dendritic cells.
The antibody was conjugated to BD Horizon™ BV480 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 436-nm and Em Max at 478-nm, BD Horizon BV480 can be excited by the violet laser and detected in the BD Horizon BV510 (525/40-nm) filter set. BV480 has less spillover into the BV605 detector and, in general, is brighter than BV510.